Replies to post #350404 on Anavex Life Sciences Corp (AVXL)

[jta1980]

Agreed but I certainly think Retts patients in South Korea and Japan should be included in estimations.

[Amatuer17]

Raja - you are right - this price will be paid only in US, some EMEA countries and Japan.

All other countries just cannot think about these numbers as drug prices - majority of people do not even earn that much in their lifetime.

This is why many new drugs are not sold in these markets - they reach those markets only at very discounted prices or reach there when they become generics

That is also the reason, all BP try to introduce new drugs in US and squeeze us

[RedShoulder]

raja, I agree with what you posted, and what I have posted does not contradict it.

When I said "small", I meant small as in very little.

Again, I just gave a "quote" from 'ReverseRett' an authority on Rett to give a view of the size of the disease world wide for information purposes, not any thing more.

350,000 is also the number Missling mentioned as the world wide figure, and like me, he did not imply that was a target number for treatments - see the transcript.

As in the dictionary:
"Small is an adjective that describes something as little or not of large size".

[sab63090]

Raja48185

You are 100% correct on that....our market exposure is only applicable to those who can afford it....so very limited and I think Missling should have said that....

I'm not the guy to discuss the science, but logic is certainly a most important factor.

[blue finch]

I again think that CM is smoking something if he thinks his number reflect realism

This is going to take a lot more time

Good post

[Bourbon_on_my_cornflakes]

Raja sees clearly: It would be wise to be conservative when coming up with world-wide numbers for patients that can afford the drug. Focus should be on US/Canada and may be Europe for cost modeling. Prices ranging 200K-500K per year are a hard-sell in places like Asia and Africa

US will be the only place with the possibility of getting $200K. National health systems will beat than number down.

Still not a problem as it would still provide a $billion+ in revenues and all the fuding needed for every future trial contemplated, and easily get our market cap over $3 billion.